Jefferies raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $96 from $83 and keeps a Buy rating on the shares after the CORE and CORE2 Phase 3 trials of olezarsen in patients with severe hyper triglyceridemia showed highly statistically significant triglyceride reductions from baseline. Following the data, the firm is increasing its estimate olezarsen peak sales to about $2.5B from $1.5B due to higher assumed penetration in sHTG.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $95 from $70 at H.C. Wainwright
- Ionis Pharmaceuticals’ Olezarsen Shows Promising Phase III Results in Reducing Triglycerides and Pancreatitis Risk
- Ionis Pharmaceuticals Announces Positive Phase 3 Study Results
- Ionis Pharmaceuticals reports CORE, CORE2 studies met primary endpoint
- Ionis Pharmaceuticals price target raised to $49 from $48 at JPMorgan